According to data made available at the annual meeting, secukinumab (SEC) 150 mg provides sustained improvement in signs, symptoms, and physical function for patients with active ankylosing spondylitis (AS) through four years of treatment.
New data presented at the annual meeting show that secukinumab (SEC) provided sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) through five years of treatment.
Systemic lupus erythematosus (SLE) is a chronic disease that causes systemic inflammation and affects multiple organs. The condition is far more common in women than in men, and pregnancy in women with lupus has long been considered a high risk for medical and obstetric complications.
New research indicates that patients with meniscal tear and osteoarthritic changes in the knee can achieve similar pain improvement in the long term whether they receive arthroscopic partial meniscectomy (APM) or physical therapy (PT).
At the annual meeting, a team of researchers presented a new method to accurately assist in the early diagnosis of ankylosing spondylitis (AS). Their study found that a genetic risk score can help clinicians identify the condition earlier and at lower cost than current testing methods.
Systemic lupus erythematosus (SLE), or lupus, is a chronic disease that causes systemic inflammation and affects multiple organs, including kidneys, lung, heart, and brain, as well as the skin and joints.